Market Backdrop
The session unfolds against a backdrop of mixed economic data released the same morning. Inflation came in essentially in line with expectations, while GDP — now in its third revision — showed a notable move to the upside. Despite these reports, the market quickly reverted to choppiness; what had been an entirely green tape early in the session gave way to back-and-forth trading within minutes.
Intraday volatility is described as a defining theme, and one likely to persist as markets digest several moving parts and crosscurrents at once. This is the closing stretch of the second quarter, and the month is shaping up to potentially be a losing one — though that outcome remains undetermined. Significant short-term headwinds are evident even though the data points themselves were broadly in line with forecasts. The key qualifier is that, while in line, those readings remain elevated.
A central open question is whether elevated inflation will roll off over the coming months. Some market participants and observers believe it will, and yields are already easing somewhat. However, the decline in yields is not yet enough to pull the market out of its current "void" — a period marked by dispersion across sectors. That dispersion is precisely the lens through which the three trade ideas are framed: identifying where strength is concentrating within an otherwise directionless tape. A recurring thesis throughout is a rotation that is expected to favor financials and healthcare in the second half of the year.
---
JPMorgan Chase (JPM) — Financials Finding Stability
The Thesis
JPMorgan is the first pick, chosen because financials appear to be finding stability and may outperform in the second half of the year as the broader rotation unfolds. JPMorgan is positioned as one of the leaders within that category. The timing is reinforced by the Federal Reserve's stress test results released the prior night, which JPMorgan passed with flying colors. On the morning of discussion, the stock was up roughly 1.75% early and the trade example had already shifted dramatically within the prior hour, with the stock breaking above the 340 level and pushing to what appeared to be new highs.Price Action and Levels
At the time of discussion the stock was trading around 339.59, having touched an intraday high of 343.45 — a new high — before pulling back about $3 to roughly 341.7, a gain of about 2% on the day. From a horizontal price perspective, the standout level is the old high near 337, above which the stock was remaining comfortably. This level had already been tested about a week earlier, which lends it significance.That same 337 area had marked a large prior decline punctuated by a big bearish engulfing candle. Crucially, that bearish pattern did not follow through the next day — and follow-through is an important component of validating that kind of candle. Because the follow-through never materialized, the stock instead retreated only to around 326, near a prior zone of old highs, before resuming its rally. The open question is whether it can mount another full-on push above the old highs.
Momentum and Moving Averages
Momentum is turning more positive. The RSI has recovered above a previous green trend line and is pushing into overbought territory, making new relative highs past its previous RSI peak. It has not yet eclipsed the older peaks from about a week ago, but it has broken the highs established a couple of sessions earlier — a more notable development.On the moving averages, the 5-day EMA (dark blue, representing one week of trading) sits near 333.78, close to the trend line, creating a confluence point to watch if price retreats. The volume profile shows no single dominant area, with moderate activity between roughly 323 and 327 (lining up with the old highs). The heaviest activity sits between about 305 and 315, with the point of control near 310.
---
Danaher Corp (DHR) — A Shifting Dynamic in Life Sciences
The Thesis
Danaher is the second pick, up about 3.25–3.5% on the session and trading around 195.37. The stock — along with other names in the life sciences and biotech space — has struggled, but the technical patterns now appear to be shifting. The argument is that rotation and renewed strength are finally taking hold, with biotech beginning to show relative strength expected to continue into the second half of the year. Thermo Fisher (TMO) is highlighted as another name that should participate if the same pattern develops, as the group forms a series of higher highs. A simple bullish tell already noted is that Danaher recently crossed above its 20-day moving average. Healthcare, the broader sector, was also having a strong day.Price Action and Levels
The stock made its push off 52-week lows established near 160.93. From that low, a trend line can be drawn — though a proper trend line ideally connects at least three low points. Duplicating and extrapolating that line across the highs produces a channel shape, and the stock is currently meeting some resistance at the channel's upper boundary.Horizontal levels of interest include lows near 175 — a notable extreme low point dating back to May that aligned with a subsequent low and roughly with some highs. A further resistance zone sits between roughly 201 and 202, defined by prior lows and subsequent highs clustering there. The RSI is not yet overbought but is close; a push into that zone would typically be read as bullish.
Moving Averages and Volume
The moving-average picture is improving: the stock has crossed above three of its moving averages very quickly over the past few sessions, with the fast 5-day EMA crossing above its slower counterparts. While such a crossover is not the strongest signal on its own, it offers an easy visual cue that conditions are improving. The 251-day EMA — representing a full year of trading — sits at 201, making it the most noteworthy level to watch. The stock stopped right at its point of control near 196.3, based on a year of trading activity. The bulk of volume forms a large block between about 187 and 212, so a move beyond either boundary would be worth noting.The Trade
How would you structure a trade given this setup? The approach is a covered call (buy-write). Buy the stock here as it appears poised to break out, then sell a January 2027 250-strike call for about $4.40. This gives roughly six to nearly seven months to capture upside toward a breakout, collect a little premium, and establish an exit point in early next year should the stock push to the 250 level. The core idea is to get long at these levels, collect premium if momentum continues, and — if not — at least lower the break-even slightly. It is framed as a longer-term play, reflecting the second-half-of-the-year thesis.---
Merck (MRK) — Coiling Toward a Breakout
The Thesis
Merck is the third pick, up about 2.6–3% on the session. The rationale again centers on the shifting dynamic within healthcare and renewed, broad-spectrum strength across the sector. Supporting names cited include UnitedHealth (showing significant strength on the insurance side), Eli Lilly, and now Merck and AbbVie as well. The argument is that a series of healthcare names are beginning to show continued upward momentum in a sector that was neglected during the first half of the year but is expected to benefit in the second half. A specific catalyst on the day was Merck's announced acquisition of a life sciences company that morning, contributing to the pop.Price Action and Levels
This is characterized as perhaps the most interesting technical setup of the three. After a range-bound period — arguably sideways, or even a converging triangular shape where two boundary lines move toward each other — the stock now sits right at the point of its best close, near 124. It has not yet taken out the prior intraday 52-week high of 125.14. This is a notable inflection point: a push above that level could trigger a cascade of orders, producing a classic breakout.The white (upward) trend line remains in play, and the stock is hanging on above its downward-sloping blue trend line as well. The key upside level is 124. To the downside, around 122 is significant — once trend lines are breached, it is common for price to retreat back to the supportive level before continuing onward after an initial breakout. This is not a prediction, simply a common pattern many traders watch, particularly those hoping to buy a dip at a lower price.
Additional horizontal reference points: 112 was a notable low before the rally began, with another low near 108, and highs and subsequent lows near 106 also worth mentioning.
Moving Averages and Volume
The 5-day EMA (dark blue) lines up closely with the trend line near 120. The 21-day EMA (teal) sits just below at about 118, offering a further supportive area. The RSI is approaching a break above a very long-term, gradual declining line; breaking above it would place the indicator within striking distance of the 70 overbought threshold. The ideal bullish scenario is a combined breakout — price and RSI both pushing above their previous highs together, especially into overbought territory. Volume forms a large clump mostly between 108 and 122, and the stock is starting to push out of that zone; once it moves into more thinly traded areas above, price could move faster.The Trade
Is there a breakout scenario built into the trade? Yes. The key level is the previous high around 125. If the stock can take that out over the next couple of weeks, continued upside momentum could take hold. The trade is a defined-risk call spread: buy the August 125/140 call spread for about $4.25, with August being just under two months out. This offers an attractive risk/reward profile for capturing further upside while defining risk should the breakout stall and fail to take hold. The preference for defined risk is explicit. The view is that above 125, a push toward the 140 level over the following two months is plausible. At the time of discussion, Merck was trading at 124.13, up 3% on the session and roughly a dollar below the highs.---
Summary of the Three Trades
| Stock | Thesis | Structure |
|-------|--------|-----------|
| JPMorgan (JPM) | Financials stabilizing and poised to lead H2 rotation; breaking above 337/340 to new highs | Directional bullish view on a breakout |
| Danaher (DHR) | Life sciences/biotech rotation and improving technicals; longer-term hold | Buy stock + sell Jan 2027 250 call for ~$4.40 (covered call) |
| Merck (MRK) | Healthcare strength plus acquisition catalyst; coiled at a 125 breakout point | Buy Aug 125/140 call spread for ~$4.25 (defined-risk) |
The unifying theme across all three is a sector rotation into financials and healthcare for the second half of the year, with technical setups in each name suggesting breakout potential — JPMorgan already pushing to new highs, Danaher reclaiming key moving averages off its lows, and Merck coiling just beneath a critical 125 resistance level.
